The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Immunosuppressive cells in tumor immune escape and metastasis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Targeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Valastyan, S., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.09.024 · Cited by 4,011
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
The cellular and molecular origin of tumor-associated macrophages
Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., Pamer, E. G., & Li, M. O. (2014) · Science · doi:10.1126/science.1252510 · Cited by 1,393
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,353
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Cancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,074
Galli, S. J., Borregaard, N., & Wynn, T. A. (2011) · Nature Immunology · doi:10.1038/ni.2109 · Cited by 1,055
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
McAllister, S. S., & Weinberg, R. A. (2014) · Nature Cell Biology · doi:10.1038/ncb3015 · Cited by 966
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767
Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R. P., & Biragyn, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4316 · Cited by 684
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M.-M., Wyckoff, J., Mertz, K. D., Varga, Z., Junt, T., & Bentires-Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 665
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Yang, P., Li, Q.-J., Feng, Y., Zhang, Y., Markowitz, G. J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.023 · Cited by 536
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M., & Swartz, M. A. (2010) · Science · doi:10.1126/science.1185837 · Cited by 506
VISTA Regulates the Development of Protective Antitumor Immunity
Le Mercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J., & Wang, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 486
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
The metastasis-promoting roles of tumor-associated immune cells
Smith, H. A., & Kang, Y. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1021-5 · Cited by 367
Goldberg, M. V., & Drake, C. G. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_114 · Cited by 337
Rech, A. J., Mick, R., Martin, S., Recio, A., Aqui, N. A., Powell, D. J., Colligon, T. A., Trosko, J. A., Leinbach, L. I., Pletcher, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003330 · Cited by 337
TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Sakuishi, K., Ngiow, S. F., Sullivan, J. M., Teng, M. W. L., Kuchroo, V. K., Smyth, M. J., & Anderson, A. C. (2013) · OncoImmunology · doi:10.4161/onci.23849 · Cited by 328
LIU, R.-Y., ZENG, Y., LEI, Z., WANG, L., YANG, H., LIU, Z., ZHAO, J., & ZHANG, H.-T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2310 · Cited by 308
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295
The origin and function of tumor-associated macrophages
Liu, Y., & Cao, X. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.83 · Cited by 291
Self-citationTargeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
Fang, H., & DeClerck, Y. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0661 · Cited by 284
Norian, L. A., Rodriguez, P. C., O'Mara, L. A., Zabaleta, J., Ochoa, A. C., Cella, M., & Allen, P. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2826 · Cited by 270
Dalotto-Moreno, T., Croci, D. O., Cerliani, J. P., Martinez-Allo, V. C., Dergan-Dylon, S., Méndez-Huergo, S. P., Stupirski, J. C., Mazal, D., Osinaga, E., Toscano, M. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2418 · Cited by 261
Thevenot, P. T., Sierra, R. A., Raber, P. L., Al-Khami, A. A., Trillo-Tinoco, J., Zarreii, P., Ochoa, A. C., Cui, Y., Del Valle, L., & Rodriguez, P. C. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.015 · Cited by 254
Parker, K. H., Sinha, P., Horn, L. A., Clements, V. K., Yang, H., Li, J., Tracey, K. J., & Ostrand-Rosenberg, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2347 · Cited by 241
Qin, H., Lerman, B., Sakamaki, I., Wei, G., Cha, S. C., Rao, S. S., Qian, J., Hailemichael, Y., Nurieva, R., Dwyer, K. C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3560 · Cited by 233
Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., et al. (2014) · Hepatology · doi:10.1002/hep.26694 · Cited by 226
Self-citationTherapeutic opportunities for manipulating TReg cells in autoimmunity and cancer
von Boehmer, H., & Daniel, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3683 · Cited by 220
RORC1 Regulates Tumor-Promoting “Emergency” Granulo-Monocytopoiesis
Strauss, L., Sangaletti, S., Consonni, F. M., Szebeni, G., Morlacchi, S., Totaro, M. G., Porta, C., Anselmo, A., Tartari, S., Doni, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.006 · Cited by 199
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
Le Mercier, I., Lines, J. L., & Noelle, R. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00418 · Cited by 195
Sawant, A., Hensel, J. A., Chanda, D., Harris, B. A., Siegal, G. P., Maheshwari, A., & Ponnazhagan, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101855 · Cited by 191
Dumitriu, I. E., Dunbar, D. R., Howie, S. E., Sethi, T., & Gregory, C. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0712671 · Cited by 171
The EGF/CSF-1 Paracrine Invasion Loop Can Be Triggered by Heregulin β1 and CXCL12
Hernández, L. B., Смирнова, Т. А., Kedrin, D., Wyckoff, J. B., Zhu, L., Stanley, E. R., Cox, D., Muller, W. J., Pollard, J. W., van Rooijen, N., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2871 · Cited by 138
Torroella‐Kouri, M., Silvera, R., Rodríguez, D., Caso, R., Shatry, A. M., Opiela, S. J., Ilkovitch, D., Schwendener, R. A., Iragavarapu‐Charyulu, V., Cardentey, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3427 · Cited by 134
Papaspyridonos, M., Matei, I. R., Huang, Y., André, M. D. R., Brazier, H., Waite, J. C., Chan, A., Kalter, J., Ramos, I., Wu, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms7840 · Cited by 120
Gertner-Dardenne, J., Fauriat, C., Orlanducci, F., Thibult, M., Pastor, S., Fitzgibbon, J., Bouabdallah, R., Xerri, L., & Olive, D. (2013) · Blood · doi:10.1182/blood-2012-11-464685 · Cited by 118
The mechanisms of cancer immunoescape and development of overcoming strategies
Yaguchi, T., Sumimoto, H., Kudo‐Saito, C., Tsukamoto, N., Ueda, R., Iwata‐Kajihara, T., Nishio, H., Kawamura, N., & Kawakami, Y. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0799-6 · Cited by 118
The origin and function of tumor-associated macrophages
Yang, Y. Y. Y., Liu, Xuetao, & Cao (2015) · 中国免疫学杂志:英文版 · Cited by 118
Zhou, Z., Sharma, V. P., Beaty, B. T., Roh‐Johnson, M., Peterson, E. A., van Rooijen, N., Kenny, P. A., Wiley, H. S., Condeelis, J. S., & Segall, J. E. (2013) · Oncogene · doi:10.1038/onc.2013.363 · Cited by 101
Prostanoid induces premetastatic niche in regional lymph nodes
Ogawa, F., Amano, H., Eshima, K., Ito, Y., Matsui, Y., Hosono, K., Kitasato, H., Iyoda, A., Iwabuchi, K., Kumagai, Y., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73530 · Cited by 98
Dimeloe, S., Frick, C., Fischer, M., Gubser, P. M., Razik, L., Bantug, G. R., Ravon, M., Langenkamp, A., & Hess, C. (2014) · European Journal of Immunology · doi:10.1002/eji.201444879 · Cited by 89
Japp, A. S., Kursunel, M. A., Meier, S., Mälzer, J. N., Li, X., Rahman, N. A., Jekabsons, W., Krause, H., Magheli, A., Klopf, C., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1752-y · Cited by 72
Lymphoma: Immune Evasion Strategies
Upadhyay, R., Hammerich, L., Peng, P., Brown, B. D., Mérad, M., & Brody, J. (2015) · Cancers · doi:10.3390/cancers7020736 · Cited by 64
Intratumoral dendritic cells in the anti-tumor immune response
Liu, Y., & Cao, X. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.130 · Cited by 48
Self-citationDepletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab
Ni, X., Langridge, T. D., & Duvic, M. A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1011524 · Cited by 47
Qian, C., Li, Q., Yu, Y., An, H., Guo, Z., Han, Y., Chen, Y., Bai, Y., Wang, Q., & Cao, X. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.425751 · Cited by 43
Self-citationHan, Y., Yang, Y., Chen, Z., Jiang, Z., Gu, Y., Liu, Y., Xu, S., Lin, C., Pan, Z., Zhou, W., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1143-4 · Cited by 38
Self-citationWu, C., Zhang, Y., Jiang, Y., Wang, Q., Long, Y., Wang, C., Cao, X., & Chen, G. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2013.16 · Cited by 30
Self-citationCastelli, C., Triebel, F., Rivoltini, L., & Camisaschi, C. (2014) · OncoImmunology · doi:10.4161/21624011.2014.967146 · Cited by 23
Kim, S., Ha, G., Kim, S., & Kang, C. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.857352 · Cited by 13
Helper T Cell Diversity and Plasticity: Possible Role in Cardiovascular Disease
Sato, K. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-1164 · Cited by 10
PI3Kδ inhibition lifts the breaks on antitumour immunity
Killock, D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.112 · Cited by 2
Cited by
Characteristics and Significance of the Pre-metastatic Niche
Liu, Y., & Cao, X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.011 · Cited by 1,269
Self-citationLactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
“In addition, TME favors the induction and recruitment of different immune cells and molecules constituting an immunosuppressive environment, favoring the development of the tumor mass (130).”
BackgroundLiu, Y., Gu, Y., Han, Y., Zhang, Q., Jiang, Z., Zhang, X., Huang, B., Xu, X., Zheng, J., & Cao, X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.021 · Cited by 640
Self-citationCurrent Progress in CAR-T Cell Therapy for Solid Tumors
Ma, S., Li, X., Wang, X., Cheng, L., Li, Z., Zhang, C., Ye, Z., & Qian, Q. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.34213 · Cited by 496
Effects of exosomes on pre-metastatic niche formation in tumors
Guo, Y., Ji, X., Liu, J., Fan, D., Zhou, Q., Chen, C., Wang, W., Wang, G., Wang, H., Yuan, W., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0995-1 · Cited by 401
Metadata
- Authors
- Liu, Y., & Cao, X.
- Venue
- Journal of Molecular Medicine
- Published
- 2015-12-22
- Volume
- 94
- Issue
- 5
- Pages
- 509-522
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- OpenAlex
- W2265131395
- Cited by
- 400
- References
- 95
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.